For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information beginning with the first discovery of GLP-1 and GIP in the body and how they worked to control glucose levels, and have included practice experience from your colleagues and other thought leaders. We have also been able to provide you some of the best Homerun Slides for you to use.
Now that the class has grown from first-in-class "Byetta" to include five unique compounds, we just released a great handout on the features and differences of each one, and just when I thought that we had covered about everything there was going on, our interns found four new studies and one new fact from the recently completed EASD meeting for you to review.
While you’re looking at those GLP-1 slides you may want to check out the Homerun Slides series by Dr. Stanley Schwartz and learn why and how his aggressive methods of treating diabetes almost always include a GLP-1 analog.
Dave Joffe, Editor-in-chief